Less Ads, More Data, More Tools Register for FREE

Pin to quick picksERGO.L Share News (ERGO)

  • There is currently no data for ERGO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: MP Evans plots payout growth; Pebble in profit swing

Tue, 23rd Mar 2021 13:00

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

MP Evans Group PLC - producer of sustainable Indonesian palm oil - Revenue in 2020 jumps 46% to USD174.5 million from USD119.3 million. Pretax profit more than doubles to USD28.4 million from USD12.8 million. Says total crop processed up 21% to 1.2 million tonnes. Crude palm oil output alone up 17% to 272,000 tonnes. "I am pleased to report that 2020 was another record year for production and revenue resulting in a sharp rise in profit," Executive Chair Peter Hadsley-Chaplin says. Raises payout by 24% to 22.00 pence per share from 17.75p. Plans 30p payout for 2021, up 36% from 2020.

----------

Pebble Group PLC - Manchester-based technology and services for promotional products industry - Revenue in 2020 falls 23% to GBP82.4 million from GBP107.2 million. However, Pebble swings to GBP5.0 million pretax profit from GBP10.3 million loss. Exceptional costs almost wiped out to GBP542,000 from GBP17.3 million. "Given the impact of the pandemic, the focus on cash preservation and the group's use of the UK Job Retention Support Scheme in the year under review, the board considers that a dividend payment in respect of 2020 would be inappropriate. We remain committed to the dividend policy stated at IPO and will review dividend payments in respect of 2021, as the new financial year progresses," Pebble adds.

----------

AMTE Power PLC - lithium-ion battery cells manufacturer - Newly-floated AMTE says revenue in six months to December 31 up 7.7% to GBP623,536 from GBP578,702 a year earlier. Pretax loss stretches to GBP1.5 million, however, from GBP856,612. Posts just GBP1.2 million in finance income, compared to GBP8.2 million a year earlier.

----------

Ergomed PLC - pharmaceutical services firm - Revenue in 2020 rises 27% to GBP86.4 million from GBP68.3 million in 2019. Pretax profit more than doubles to GBP12.6 million from GBP5.0 million. "We have been able to adapt our business model to the challenge and are proud to play a role in helping to combat the disease [Covid-19]. We are confident that we will continue to be able to bring our expertise and proven capabilities to bear in advancing drug development in the field and improving outcomes for patients," Ergomed says.

----------

Judges Scientific PLC - London-based scientific instrument sector investor - Revenue in 2020 down 3.2% to GBP79.9 million from GBP82.5 million. Pretax profit falls 31% to GBP9.5 million from GBP13.6 million, but Judges notes that it secured "significant profit" in every month of year, despite Covid-19 pressure. Ordinary dividend raised by 10% to 55.0 pence per share from 50.0p. However, Judges paid a GBP2 special dividend in 2019.

----------

Symphony International Holdings Ltd - Hong Kong-based investor - Net asset value per share falls 25% to USD0.7384 at the end of 2020, from USD0.9805 at the end of 2019. "Despite a challenging year, Symphony's portfolio companies were able to weather 2020, albeit with some mixed results. Sectors, such as hospitality and lifestyle, where we have traditionally had a large exposure, have been materially impacted, but most investee companies in other sectors returned to positive growth during the latter half of the year," Symphony says.

----------

Temple Bar Investment Trust PLC - investment trust - Net asset value per share at end of 2020 down 31% to 1,009.88p from 1,473.13p a year earlier. "The results for the year ended 31 December 2020 overall were very disappointing," Temple Bar says. Cuts total payout by 25% to 38.5p per share from 51.39p.

----------

Anglo African Agriculture PLC - agriculture investment company - Revenue in year ended October 31 falls 2.5% to GBP1.77 million from GBP1.82 million. Pretax loss widens to GBP1.0 million from GBP284,665. Administrative expenses almost double to GBP1.1 million from GBP621,411.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
19 Sep 2018 12:26

Ergomed Sinks To Interim Loss As Costs Rise In Spite Of Revenue Growth

LONDON (Alliance News) - Pharmaceutical services company Ergomed PLC said on Wednesday it swung to a loss for the first half of 2018 due to higher expenses and in spite of revenue the six months a

Read more
2 Jul 2018 11:02

Ergomed Appoints Stuart Jackson As Chief Financial Officer

LONDON (Alliance News) - Pharmaceutical services provider Ergomed PLC said on Monday it has appointed Stuart Jackson as chief financial officer with immediate effect.Previously, Jackson was

Read more
17 Apr 2018 18:07

Strategic Equity Takes Holding In Ergomed Across Notifiable Threshold

LONDON (Alliance News) - Ergomed PLC said Tuesday that Strategic Equity Capital PLC took its stake in the company to 5.3%.Prior to Monday's transaction it was not disclosed what holding

Read more
4 Apr 2018 15:58

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 5 April ElectrocomponentsTrading statementHSS Hire GroupFull Year Year Airlines

Read more
6 Feb 2017 09:24

Ergomed reports positive results from insomnia drug trial

(ShareCast News) - AIM-listed pharma company Ergomed on Monday reported positive top-line results from a Phase II clinical trial of Lorediplon in patients with insomnia with its co-development partner Ferrer. The company said both 5 and 10mg Lorediplon met the primary endpoint with "high statistical

Read more
29 Nov 2016 09:07

Ergomed buys drug safety and regulatory consultancy for £4m

(ShareCast News) - AIM-listed pharmaceutical Ergomed has bought Prague-based European PharmInvent Services for €4.8m (£4.1m), in order to grow its services business. The acquisition of PharmInvent, a drug safety and regulatory consultancy, will expand the company's pharmacovigilance division, PrimeV

Read more
29 Nov 2016 09:03

Ergomed Boosts PrimeVigilance Division By Purchasing PharmInvent (ALLISS)

Read more
24 Oct 2016 07:58

Ergomed Co-Development Partner Plans Name Change And Listing

Read more
14 Oct 2016 11:35

Ergomed to benefit from Zoptrex Australasia deal

(ShareCast News) - Specialised pharmaceutical services company Ergomed announced on Friday that its co-development partner, Aeterna Zentaris, has signed an additional licensing agreement for Zoptrex. The AIM-traded firm said Aeterna Zentaris signed an exclusive license agreement on Wednesday with Sp

Read more
19 Sep 2016 15:05

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
2 Sep 2016 09:27

Ergomed wins two licenses for cancer drug Zoptrex

(ShareCast News) - Pharmaceutical service provider Ergomed's development partner Aeterna Zentaris, won two licensing deals for its cancer drug Zoptrex gaining new territory in Southeast Asia and the Middle East. In July 2016 Aeterna Zentaris signed a license agreement with affiliates of Orient EuroP

Read more
20 Jul 2016 15:07

UK Shareholder Meetings Calendar - Next 7 Days

Read more
27 Jun 2016 09:41

Ergomed Opens New US Office For PrimeVigilance Business Outside Boston

Read more
13 Jun 2016 14:03

Ergomed buys two German service companies

(ShareCast News) - Ergomed, a British pharmaceutical development services company, said on Monday, it had bought two German service providers to complement and enhance its existing capabilities, and increase its presence in Germany. The company acquired Dr. Oestreich + Partner GmbH (O+P), a full ser

Read more
13 Jun 2016 06:57

Ergomed Buys Two German Service Providers To Enhance Capabilities (ALLISS)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.